Hussein A. Tawbi, MD, PhD - New Rules for Sequential Care in BRAF-Mutated Melanoma: Rethinking Upfront Selection and Sequencing of Immunotherapy and Targeted Agents in Metastatic Disease

Go online to PeerView.com/ZBX860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. Treatment advances in metastatic melanoma have been
characterized by the use of immunotherapy, including PD-1 and
CTLA-4 checkpoint inhibitors, as well as targeted agents in
BRAF-mutated disease—and collectively these modalities represent
the driving forces leading to improved clinical outcomes across
disease settings. How will new evidence change this current
paradigm? In this MasterClass & Case Forum video activity,
based on a live event at the 2022 ASCO Annual Meeting, an expert
panel explores the latest practice-changing clinical evidence for
managing BRAF-mutated melanoma, while providing case-based
practical guidance on modern treatment decisions with immunotherapy
and targeted agents. Learn how these experts are using novel
immune-based options in this setting to improve outcomes for their
patients with BRAF-mutated disease. Upon completion of this
activity, participants should be better able to: Cite current
evidence on the efficacy of modern sequential approaches to using
immunotherapy and targeted regimens in the setting of BRAF-mutated,
metastatic melanoma; Utilize optimized strategies with
immunotherapy components for the initial and sequential management
of patients with BRAF-mutated, metastatic melanoma; and Develop
team-based, collaborative strategies for managing toxicity
associated with the sequential use of immunotherapy and targeted
agents in patients with metastatic melanoma.